MARKETS / NASDAQ / XRAY

NASDAQ · DENTAL EQUIPMENT & SUPPLIES · LARGE CAP

Dentsply Sirona Inc. XRAY

19 fiscal years on record · USD · FY2025 reported · SEC filings only

Revenue

$3.7B

▼ 3.0% YoY

Net income

$-598.0M

Free cash flow

$104.0M

▼ 63.0% YoY

In brief

What this company does

DENTSPLY SIRONA Inc. develops, manufactures and markets dental equipment supported by cloud-enabled software, dental products, and healthcare consumable products for urology and enterology. The Company sells products globally through its foreign subsidiaries to customers in approximately 140 countries. As of December 31, 2025, the Company and its subsidiaries employed approximately 14,000 employees globally, including approximately 3,000 in the United States. The Company conducts business through four reportable segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment includes the design, manufacture and sales of the Company's dental technology and equipment products, including its Equipment & Instruments and computer-aided design/computer-aided manufacturing product categories. The Essential Dental Solutions segment includes the development, manufacture and sales of the Company's endodontic, restorative, and preventive consumable products and small equipment used by dental professionals for the treatment of patients. The Orthodontic and Implant Solutions segment includes the design, manufacture, and sales of the Company's digital implant systems, dental implant products, digital dentures, and digital orthodontic solutions. The Wellspect Healthcare segment includes the design, manufacture, and sales of the Company's continence care solutions for both urinary and bowel management.

Written from the business description in DENTSPLY SIRONA Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth

USD 3.7B

Revenue, FY2025 · full 19-year series below

Revenue $B Net income $B

FY2025 · Revenue 3.7 · Net income -0.6

Compound annual growth

Revenue

−2.1%

+2.0%

+3.2%

+3.4%

Dividend / share

+8.6%

+9.9%

Returned to shareholders

−19.8%

−10.0%

+0.9%

−3.6%

3 yrs

5 yrs

10 yrs

15 yrs

Revenue compounded at +2.0% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−16 cents

lost on every revenue dollar

Operating margin Net margin

FY2025 · Operating -11.5% · Net -16.2%

ROE

FY2025 · ROE -36.5%

Gross margin50.0%

Operating margin-11.5%

Net margin-16.2%

Return on assets-10.7%

EBITDAUSD -70.0M

Each USD of equity lost 36 cents this year.

Cash & shareholders

USD 128.0M

returned in FY2025 · dividends + net buybacks

Free cash flow $M

FY2025 · FCF 104.0

Net buybacks $M Dividends $M

FY2025 · Dividends 128.0 · Net buybacks 0.0

Dividends paidUSD 128.0M

Net buybacksUSD 0.00

Share of profit-21.4%

Consecutive raises—

USD 128.0M in dividends went back to shareholders in a year without profit.

Total assetsUSD 5.4B

EquityUSD 1.3B

CashUSD 326.0M

Gross debtUSD 2.2B

Net debtUSD 1.9B

Current ratio1.51×

Net debt stands at 143% of equity.

The 19-year record

19 fiscal years

Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Revenue $B	3.7	3.8	4.0	3.9	4.2	3.3	4.0	4.0	4.0	3.7	2.7	2.9	3.0	2.9	2.5	2.2	2.2	2.2	2.0
Operating income $B	−0.4	−0.9	−0.1	−0.9	0.6	−0.0	0.4	−1.0	−1.6	0.5	0.4	0.4	0.4	0.4	0.3	0.4	0.4	0.4	0.4
EBITDA $B	−0.1	−0.5	0.3	−0.6	1.0	0.3	0.7	−0.6	−1.2	0.7	0.5	0.6	0.5	0.5	0.4	0.4	0.4	0.4	0.4
Income tax $B	0.1	−0.0	−0.0	−0.1	0.1	0.0	0.1	0.1	−0.1	0.0	0.1	0.1	0.1	0.0	0.0	0.1	0.1	0.1	0.1
Net income $B	−0.6	−0.9	−0.1	−0.9	0.4	−0.1	0.3	−1.0	−1.6	0.4	0.3	0.3	0.3	0.3	0.2	0.2	0.3	0.3	0.3
Free cash flow $B	0.1	0.3	0.2	0.4	0.5	0.6	0.5	0.3	0.5	0.4	0.4	0.5	0.3	0.3	0.3	0.3	0.3	0.3	0.3
EPS, diluted $	−3.00	−4.48	−0.62	−4.41	1.87	−0.33	1.14	−4.51	−6.76	1.94	1.76	2.24	2.16	2.18	1.70	1.82	1.83	1.87	1.68
Dividend / sh $	0.64	0.64	0.56	0.50	0.43	0.40	0.38	0.35	0.35	0.31	0.29	0.27	0.25	0.22	0.20	0.20	0.20	0.18	0.17
Payout %	−21	−14	−88	−11	22	−121	32	−8	−5	15	16	12	11	10	12	11	11	9	10
ROE %	−36.5	−34.8	−3.7	−21.6	8.3	−1.5	5.0	−17.2	−21.0	8.2	10.8	13.3	13.2	15.5	13.3	14.5	16.0	17.9	·
Shares out B	0.20	0.20	0.21	0.22	0.22	0.22	0.22	0.22	0.23	0.23	0.14	0.14	0.14	0.14	0.14	0.14	0.15	0.15	0.15

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance

Company facts, as filed

How we verify · 0 failures in 93 reconciliationsAUDITED

Reconciled in 19 of 19 fiscal years. 2 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures

ActivityDental Equipment & Supplies

Listed onNASDAQ

Incorporated inDelaware

Fiscal year endsDecember 31

Data on record since2007